<DOC>
	<DOCNO>NCT00002186</DOCNO>
	<brief_summary>To evaluate safety topically apply SP-303 gel compare efficacy SP-303 gel combination acyclovir , relative acyclovir alone , treatment recurrent Herpes Simplex Virus ( HSV ) 1 2 infection , affect genital , perianal neighbor area , patient AIDS .</brief_summary>
	<brief_title>Double-Blind Placebo-Controlled Study Comparing Combination 15 % SP-303 Gel With Acyclovir Versus Acyclovir Alone Treatment Recurrent Herpes Simplex Virus ( HSV ) Infections Subjects With Acquired Immunodeficiency Syndrome ( AIDS )</brief_title>
	<detailed_description>This trial double-blind , multicenter , placebo-controlled clinical trial . Participants randomize topical 15 % SP-303 gel oral acyclovir match topical placebo gel oral acyclovir . At presentation , patient stratify total lesion area within treatment group . SP-303 match placebo topically apply three time day lesion reepithelialized 14 day , whichever occur early . Acyclovir administer mouth day , three time day , lesion reepithelialized 14 day , whichever occur early . Patients evaluated lesion heal adverse event 3 time per week treatment period . The primary efficacy endpoint complete lesion heal primary analysis time complete healing .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria Patients must : AIDS , accord CDC criterion . Documented recurrent ( least 1 prior episode ) perineal ( genital , perianal neighbor area ) mucocutaneous herpes simplex virus ( HSV ) type 1 2 infection active phase . Duration current episode recurrent HSV lesions 3 day less . Ability read write , must intellectually competent , able understand purpose risk study . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active internal anal rectal herpes . Inability comply protocol . Impaired renal function . Patients follow prior condition exclude : Prior episode recurrent genital herpes infection document clinical failure acyclovir treatment regimen . Uncompensated hepatic , cardiac , renal failure within 1 month study . History hypersensitivity acyclovir . Previous enrollment study . 1 . Treatment another medication ( topical , oral , intravenous ) know antiHSV activity within past 5 day . Systemic immunomodulatory therapy within 30 day prior study . Previous treatment SP303 . Required : Unchanged antiretroviral therapy 2 week prior study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1998</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Herpes Simplex</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acyclovir</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Gels</keyword>
	<keyword>SP 303</keyword>
</DOC>